Levitee Labs / Press Releases

Latest news

Levitee Labs is on a mission to elevate the wellbeing of society

Become an investor

Press Releases

Learn more about how Levitee Labs is blending traditional health systems with the new frontier of value based health solutions, including psychedelic medicines and digitization, for better patient outcomes

12/01/22

Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals

10/01/22

Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids

06/01/22

Levitee Labs Announces Medical Advisory Board

20/12/21

Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

15/11/21

Levitee Labs Appoints Noha ElSayed as Executive Director for Levitee Clinics and Levitee Pharmacies in the Alberta Region

10/11/21

Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia

08/11/21

Levitee Labs Publishes First Combined Revenue Figures for September 2021 and October 2021

08/11/21

Levitee Labs Signs LOI to Acquire Controlling Interest in a R&D Compounding Pharmacy; Focus to be on Levitee-Branded Products

28/10/21

Levitee Clinics and Levitee Pharmacies Provide Insight on Integrated Acquisition Strategy for its Addiction and Pain Services

21/10/21

Levitee Labs Enters into Credit Facility For Up To $12 Million

18/10/21

Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions

14/10/21

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

12/10/21

Levitee Labs Signs Letter of Intent to Acquire Calgary Addiction and Compounding Pharmacy

05/10/21

Levitee Labs Publishes First Revenue Figures for August 2021

01/10/21

Levitee Labs Announces Listing On Frankfurt Stock Exchange

24/09/21

Levitee Labs Announces DTC Eligibility Approval

09/09/21

Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

10/08/21

Levitee Labs Announces Azim Qazi as Head of Ecommerce and Consumer Packaged Goods

05/08/21

Levitee Labs Appoints NIH Physician-Scientist Dr. Fady Hannah-Shmouni as Chief Medical and Scientific Officer

04/08/21

Levitee Labs Completes Acquisition of Earth Circle Organics, Adds Superfoods Company to Portfolio

29/07/21

Levitee Labs Acquires Five Addiction Clinics in Alberta

29/07/21

Levitee Labs Acquires Three Specialized Alberta Pharmacies

28/07/21

Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform

23/07/21

Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company in Alberta

22/07/21

Levitee Labs Provides Company Update Following CSE Listing

19/07/21

Levitee Labs to Commence Trading on the Canadian Securities Exchange Under the Ticker Symbol “LVT” on Wednesday, July 21st 2021

17/02/21

Levitee Labs Announces Closing of Oversubscribed Private Placement

Would you like to know more?